Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Economic Conundrum for Antibacterial Drugs.

Literature DB >> 31658969

The Economic Conundrum for Antibacterial Drugs.

Abstract

While resistance to antibacterial drugs is increasing globally, it is unevenly distributed. The number of cases that are truly difficult to treat remain below the number required to drive an adequate market for needed new therapies. Without a sufficient market, companies pursuing these drugs risk financial failure. Here, I explore, at least briefly, the current situation and the financial risks to companies. I provide potential solutions to the failed market.

Entities: Disease

Keywords: antibacterial drugs; antibacterial research; antimicrobial resistance; commercial markets; drug development

Year: 2019 PMID： 31658969 PMCID： PMC7187572 DOI： 10.1128/AAC.02057-19

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

11 in total

Review 1. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals.

Authors: D M Shlaes; D N Gerding; J F John; W A Craig; D L Bornstein; R A Duncan; M R Eckman; W E Farrer; W H Greene; V Lorian; S Levy; J E McGowan; S M Paul; J Ruskin; F C Tenover; C Watanakunakorn
Journal: Clin Infect Dis Date: 1997-09 Impact factor: 9.079

2. Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.

Authors: Deanna J Buehrle; Ryan K Shields; Lloyd G Clarke; Brian A Potoski; Cornelius J Clancy; M Hong Nguyen
Journal: Antimicrob Agents Chemother Date: 2016-12-27 Impact factor: 5.191

3. Emerging Resistance, New Antimicrobial Agents … but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape.

Authors: R M Humphries; J A Hindler
Journal: Clin Infect Dis Date: 2016-03-29 Impact factor: 9.079

4. Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae.

Authors: Cornelius J Clancy; M Hong Nguyen
Journal: Antimicrob Agents Chemother Date: 2019-10-07 Impact factor: 5.191

5. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents.

Authors: Sameer S Kadri; Jennifer Adjemian; Yi Ling Lai; Alicen B Spaulding; Emily Ricotta; D Rebecca Prevots; Tara N Palmore; Chanu Rhee; Michael Klompas; John P Dekker; John H Powers; Anthony F Suffredini; David C Hooper; Scott Fridkin; Robert L Danner
Journal: Clin Infect Dis Date: 2018-11-28 Impact factor: 9.079

6. Daily cost of delay to adequate antibiotic treatment among patients surviving a hospitalization with community-onset Acinetobacter baumannii pneumonia or sepsis.

Authors: Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Weihong Fan; Andrew F Shorr
Journal: Crit Care Date: 2017-06-05 Impact factor: 9.097

7. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.

Authors: Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Weihong Fan; Andrew F Shorr
Journal: BMC Infect Dis Date: 2017-04-17 Impact factor: 3.090

8. Pseudomonas aeruginosa urinary tract infections in hospitalized patients: Mortality and prognostic factors.

Authors: Jose Luis Lamas Ferreiro; Judith Álvarez Otero; Lucía González González; Luis Novoa Lamazares; Alexandra Arca Blanco; Jose Ramón Bermúdez Sanjurjo; Irene Rodríguez Conde; María Fernández Soneira; Javier de la Fuente Aguado
Journal: PLoS One Date: 2017-05-26 Impact factor: 3.240

9. Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data.

Authors: Cornelius J Clancy; Brian A Potoski; Deanna Buehrle; M Hong Nguyen
Journal: Open Forum Infect Dis Date: 2019-07-28 Impact factor: 3.835

10. Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality.

Authors: Kevin Outterson; Unni Gopinathan; Charles Clift; Anthony D So; Chantal M Morel; John-Arne Røttingen
Journal: PLoS Med Date: 2016-06-14 Impact factor: 11.069

5 in total

Review 1. Clinical Utility of Lefamulin: If Not Now, When?

Authors: Nicholas J Mercuro; Michael P Veve
Journal: Curr Infect Dis Rep Date: 2020-07-09 Impact factor: 3.725

Review 2. Collaborative Platform Trials to Fight COVID-19: Methodological and Regulatory Considerations for a Better Societal Outcome.

Authors: Olivier Collignon; Carl-Fredrik Burman; Martin Posch; Anja Schiel
Journal: Clin Pharmacol Ther Date: 2021-03-16 Impact factor: 6.903

3. The Production of Antibiotics Must Be Reoriented: Repositioning Old Narrow-Spectrum Antibiotics, Developing New Microbiome-Sparing Antibiotics.

Authors: Sylvain Diamantis; Nicolas Retur; Benjamin Bertrand; Florence Lieutier-Colas; Philippe Carenco; Véronique Mondain
Journal: Antibiotics (Basel) Date: 2022-07-08

4. The Triprenylated Anthranoid Ferruginin A, a Promising Scaffold for the Development of Novel Antibiotics against Gram-Positive Bacteria.

Authors: Bruno Casciaro; Francesca Ghirga; Floriana Cappiello; Valeria Vergine; Maria Rosa Loffredo; Silvia Cammarone; Elena Puglisi; Carola Tortora; Deborah Quaglio; Mattia Mori; Bruno Botta; Maria Luisa Mangoni
Journal: Antibiotics (Basel) Date: 2022-01-11

5. There is no market for new antibiotics: this allows an open approach to research and development.

Authors: Dana M Klug; Fahima I M Idiris; Mark A T Blaskovich; Frank von Delft; Christopher G Dowson; Claas Kirchhelle; Adam P Roberts; Andrew C Singer; Matthew H Todd
Journal: Wellcome Open Res Date: 2021-06-11

5 in total